## Ralf Kronenwett

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6460501/publications.pdf

Version: 2024-02-01

1040056 1474206 1,325 9 9 9 citations h-index g-index papers 9 9 9 1553 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Annals of Surgical Oncology, 2020, 27, 765-771.	1.5	19
2	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. European Journal of Cancer, 2020, 134, 99-106.	2.8	29
3	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2â° Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clinical Cancer Research, 2019, 25, 3865-3872.	7.0	54
4	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment, 2019, 176, 377-386.	2.5	61
5	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	7.1	246
6	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute, 2016, 108, djw149.	6.3	165
7	Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer, 2012, 12, 456.	2.6	66
8	Decentral gene expression analysis for ER+/Her2â^' breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 251-259.	2.8	88
9	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clinical Cancer Research, 2011, 17, 6012-6020.	7.0	597